The trusted network for EU health data collaboration.
Pollen Compute builds a community of hospitals, research labs, and pharma — collaborating on clinical evidence, medical research, and population health, around a new privacy standard.
Biotech and pharma have poured billions into drug discovery and clinical development — chasing shorter timelines and lower costs for diseases that resisted every previous approach. AI has dramatically compressed preclinical discovery — and quantum-accelerated discovery, on the horizon, will push that further.
But clinical development is stuck. The bottleneck has shifted from finding the molecule to proving it works — and proof requires data at scale. Public data is abundant, but the valuable clinical knowledge stays in confidential silos. Healthcare is hitting a data foundation ceiling, not an algorithmic one.
The technical workarounds keep failing. De-identified datasets get re-identified — and re-identification capability is escalating with modern AI. Centralizing patient records in a third-party processor is itself the failure: one breach exposes everyone.
Security and privacy keep the data locked — and the regulator is now blocking the workarounds. Multiple EU bodies have ruled the existing architecture inadequate: data protection authorities escalated enforcement against pseudonymization-based pharma RWE, guidelines confirm pseudonymized data remains personal data, and the Court of Justice affirmed hospital controller liability persists. De-identification incumbents cannot operate in the strictest EU markets. The gap is symmetrical: EHDS requires hospitals to make data available by 2029, but the architecture to do it doesn't exist yet. A trusted layer is missing.
Knowledge moves, data doesn't. Our cryptographer team shifts the paradigm — data stays encrypted, computation runs on the encrypted data itself, so raw data is never exposed at any point.
The result: institutions collaborate without exchanging raw data — only the result leaves. RWE studies become easier and faster for pharma, Phase III patient selection sharpens, hospitals turn previously-locked data into research output and EHDS readiness, research consortia and public-health agencies query across borders without months of approvals, and data access cycles drop from years to days. With EHDS coming into force, this trusted layer fills the gap EU regulation now mandates — across clinical development, medical research, and population health.
Data is never exposed.
Mathematically guaranteed.
On top of encryption at rest and in transit, data is now encrypted in use. The mathematics — not policy or trust — make it impossible for any party to see what they should not see.
Cryptographic privacy-preserving computation libraries reached production-grade performance. Hardware-trust alternatives — TEE, confidential computing — have been systematically broken in recent attacks, leaving cryptography as the only mathematical guarantee. And the pharma trade body has formally identified the unmet need for cryptographic protection of model IP and processed insights. The architecture and the demand are aligned for the first time.
Privacy
Computation runs directly on encrypted data. Neither Pollen nor any third party can ever decrypt the data. Pollen is built on production-grade post-quantum cryptographic libraries — open-source, audited, and developed at the world's leading research institutions.
Governance & Compliance
Data Use Agreements govern every action: the data owner chooses who computes, what's allowed, and revokes access at any time. Every query produces an audit trail. Designed against EHDS requirements and binding EDPB guidance on pseudonymized health data.
Reliability
Data is harmonized before any computation runs — so results are statistically meaningful and comparable across hospitals.
Privacy is the foundation.
Product feels nothing encrypted.
Three architectural layers — privacy, computation, collaboration management — plus the apps and integrations on top. The cryptography is invisible to the day-to-day user.
Pollen is the trusted third party for EU pharma-hospital collaboration. A workspace that fits your team, apps that map to your R&D plan, integrations that don't break your EHR, governance that your legal team can approve in hours, and a compute layer that's mathematically uncompromised. Pollen is all five.
Apps
Cohort Count · Kaplan-Meier · Cox Regression · Propensity Match · Pharmacovigilance · Model Inference · HTA Evidence · …
Collaboration management
Data Use Agreements · Audit trail · Workspace · Reporting · Synthetic-data preview
Computation engines
Statistics · ML & AI · Cohort queries · Aggregates · PSI · Encrypted queries · Secure aggregation
Privacy-preserving foundation
Privacy-Enhancing Technologies
Adapters
Pollen runs on the EHR you already have.
One trusted network. Multiple unlocked collaborations.
Turn EHR data into a usable foundation — fresh, auditable, harmonized, regulator-survivable. Privacy and security make it collaborative — across audiences, levels, and incentives.
Real-time pharmacovigilance & safety surveillance
Detect drug safety signals on live hospital EHR.
Post-approval RWE studies
Cohort queries across hospital EHRs. Real-world evidence for HTA bodies without a single patient record moving.
Run your proprietary model
Pollen encrypts your model. Neither Pollen nor hospitals see it. IP and patient records both stay private.
Trial feasibility & site selection
Before committing to Phase III, size the target patient cohort across the network and identify the right sites in days instead of months. Without revealing inclusion criteria or identifying any patient.
Federated external control arms
Real hospital patients as historical controls for rare-disease and oncology submissions — without centralized data extraction or months of per-hospital approvals.
For pharma, hospitals, research.
Different incentives. One network.
Each new member compounds the value: pharma gains evidence at scale, hospitals unlock research output and a new revenue stream, research and public-health agencies query across hospitals without months of approvals.
Hospital EHR data is impossible to access at scale today. Pollen unlocks an EU market that doesn't exist yet. On top of that, clinical EHR depth in weeks, enough to validate Phase III patient populations before €200–500M trial commits. And the protection runs both ways: run proprietary models on hospital data without exposing them. Pharma IP and patient records both stay private.
Analytics across hospitals unlock clinical capability only a network produces — up-to-date reference ranges, rare-disease cohorts no single hospital can build alone, less-biased ML on diverse populations, multicentric studies without months of approvals, and pharma-sponsored research. The posture that recruits top clinicians and wins EU-wide partnerships. Two more reasons close the case: EHDS Health Data Holder readiness for the 2029 obligation, and a new sustainable revenue stream.